Alterity Therapeutics (ASX:ATH) Retained Earnings: A$-234.38 Mil (As of Dec. 2025)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
33 GF Score
Price A$0.71
View Full Analysis

What is Alterity Therapeutics Retained Earnings?

Alterity Therapeutics ASX:ATH +5.97% 33 Retained Earnings is A$-234.38 Mil as of Dec. 2025. GuruFocus rates ASX:ATH with a GF Score™ of 33/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Alterity Therapeutics's retained earnings for the quarter that ended in Dec. 2025 was A$-234.38 Mil.

Alterity Therapeutics's quarterly retained earnings increased from Jun. 2025 (A$-225.89 Mil) to Sep. 2025 (A$0.00 Mil) but then declined from Sep. 2025 (A$0.00 Mil) to Dec. 2025 (A$-234.38 Mil).

Alterity Therapeutics's annual retained earnings declined from Jun. 2023 (A$-195.13 Mil) to Jun. 2024 (A$-214.16 Mil) and declined from Jun. 2024 (A$-214.16 Mil) to Jun. 2025 (A$-225.89 Mil).


Alterity Therapeutics  (ASX:ATH) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Alterity Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Retained Earnings Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -169.73 -181.88 -195.13 -214.16 -225.89

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -225.89 0.00 -234.38 0.00
ASX:ATH
33GF Score
Alterity Therapeutics Ltd ASX:ATH
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of A$-234.38 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Retained Earnings of A$-234.38 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Retained Earnings too high?
Alterity Therapeutics' current Retained Earnings is A$-234.38 Mil. Overall, Alterity Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Retained Earnings compare to VRTX and REGN?
Alterity Therapeutics' Retained Earnings of A$-234.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Retained Earnings is A$-234.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Retained Earnings of A$-234.38 Mil. The current Retained Earnings is A$-234.38 Mil. Alterity Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Retained Earnings is A$-234.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
33GF Score

Get the complete analysis for ASX:ATH

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.71
Price